Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous NK cells + nimotuzumab
- Development stage
- Unknown
- Lead developer
- Shixiu Wu
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
autologous NK cells + nimotuzumab is an investigational combination immunotherapy being developed by Hangzhou Cancer Hospital for the treatment of advanced, recurrent, or metastatic cancers. The therapy involves the adoptive transfer of a patient's own natural killer (NK) cells in combination with nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Nimotuzumab binds to EGFR-expressing tumor cells, while the infused NK cells, which express the activating Fc receptor CD16a, recognize the antibody-coated cells and initiate antibody-dependent cellular cytotoxicity (ADCC). This dual approach aims to enhance the innate anti-tumor activity of NK cells through targeted antibody-mediated recruitment and direct tumor cell lysis, potentially overcoming immune evasion in EGFR-positive malignancies.
- Other names
- NK Cell adaptive transfer + nimotuzumabautologous natural killer cell adoptive transfer + nimotuzumab
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on autologous NK cells + nimotuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous NK cells + nimotuzumab.